TriangleNCT00101283 · OUTCOME
Progression-Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Assessed every 3 months for 2 years, then every 6 months for 1 year
What was measured
Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.
Analysis population: The population consisted of all eligible, treated patients. 3 patients randomized to pemetrexed/gemcitabine who withdrew prior to treatment are excluded.
Groups in this outcome
Pemetrexed/Carboplatin
Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to AUC 5 IV over 30 minutes on day 1 of a 21-day cycle.
Pemetrexed/Gemcitabine
Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
| Group | Source count |
|---|---|
| Pemetrexed/Carboplatin | 16 |
| Pemetrexed/Gemcitabine | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pemetrexed/Carboplatin | 4.1 | Not reported | 1.7 | 6.6 | Not reported |
| Pemetrexed/Gemcitabine | 3.3 | Not reported | 1.6 | 5.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.7
- upper Limit
- 6.6
- value
- 4.1
- group Id
- OG001
- lower Limit
- 1.6
- upper Limit
- 5.2
- value
- 3.3
- denoms
- counts
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 13
- units
- Participants
- description
- Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to AUC 5 IV over 30 minutes on day 1 of a 21-day cycle.
- id
- OG000
- title
- Pemetrexed/Carboplatin
- description
- Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
- id
- OG001
- title
- Pemetrexed/Gemcitabine
- param Type
- MEDIAN
- population Description
- The population consisted of all eligible, treated patients. 3 patients randomized to pemetrexed/gemcitabine who withdrew prior to treatment are excluded.
- reporting Status
- POSTED
- time Frame
- Assessed every 3 months for 2 years, then every 6 months for 1 year
- title
- Progression-Free Survival
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice